Q3 Earnings Estimate for TMO Issued By William Blair

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities researchers at William Blair issued their Q3 2025 earnings per share estimates for Thermo Fisher Scientific in a research note issued to investors on Monday, August 18th. William Blair analyst M. Larew anticipates that the medical research company will post earnings per share of $5.50 for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. William Blair also issued estimates for Thermo Fisher Scientific’s Q4 2025 earnings at $6.44 EPS, FY2025 earnings at $22.44 EPS, Q1 2026 earnings at $5.71 EPS, Q2 2026 earnings at $5.92 EPS, Q3 2026 earnings at $6.07 EPS, Q4 2026 earnings at $6.83 EPS, FY2026 earnings at $24.53 EPS, Q1 2027 earnings at $6.33 EPS, Q2 2027 earnings at $6.57 EPS and FY2027 earnings at $27.17 EPS.

A number of other research firms have also weighed in on TMO. Robert W. Baird upped their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. HSBC reaffirmed a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Finally, Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $593.00.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $494.8160 on Thursday. The company has a market cap of $186.85 billion, a PE ratio of 28.62, a P/E/G ratio of 2.66 and a beta of 0.74. The firm’s 50 day moving average price is $439.69 and its 200-day moving average price is $458.78. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the firm earned $5.37 earnings per share. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $52,037,916.68. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock worth $8,345,792 in the last 90 days. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of large investors have recently bought and sold shares of TMO. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $25,000. CBIZ Investment Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $30,000. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Finally, Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.